- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03766178
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
A Single-arm, Open Phase II Clinical Trial of Anti-PD-1 Antibody SHR-1210 Combined With Nimotuzumab as Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18~75 years, both men and women.
- Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC), and locally advanced unresectable, local recurrence or distant metastasis.
- Patients undergoing first-line systemic chemotherapy (which may include platinum, lavender or fluorouracil) progression or intolerance (progress in maintenance therapy after first-line chemotherapy can also be included). Synchronous chemoradiotherapy for postoperative recurrence or metastasis is considered as first-line treatment; For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, Count it as a first-line treatment failure.
- At least one measurable/evaluable lesion by RECIST v1.1. And the measurable lesions should not have received local treatment such as radiotherapy (The lesion located in the previous radiotherapy area, if confirmed to progress, and meets the RECIST 1.1 standard, can also be used as a target lesion).
- EGFR immunohistochemistry or FISH detection was positive in tumor tissue samples.
- Tissue samples shall be provided for biomarker analysis, preferably newly acquired tissues, and patients who are unable to provide newly acquired tissues may provide 5-8 pieces of 5um thick paraffin sections that are archived and preserved.
- Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.
- Life expectancy of ≥ 12 weeks.
- The main organs function normally, that is, the following criteria are met:
(1) Blood routine examination:
- HB≥90g/L;
- ANC ≥ 1.5 × 109 / L;
- PLT ≥ 80 × 109 / L. (2) Biochemical examination:
a. ALB ≥ 30g / L; b. ALT and AST ≤ 2.5ULN; if there is liver metastasis, ALT and AST ≤ 5ULN; c. TBIL ≤ 1.5ULN; d. plasma Cr ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min. 10. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF)≥ normal low limit (50%).
11. Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months of the end of the study; the serum or urine pregnancy test is negative within 7 days prior to study enrollment, and Must be non-lactating; males should agree to use contraceptives during the study period and within 6 months of the end of the study period.
12. Subjects voluntarily joined the study, signed informed consent, and were well-adhered to follow-u.
Exclusion Criteria:
- The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid Hyperfunction; patients with vitiligo; complete remission of asthma in childhood, can be included without any intervention after adult; asthma patients who require bronchodilators for medical intervention cannot be included).
- The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose >10 mg/day of prednisone or other therapeutic hormones) and continues to be used within 2 weeks prior to enrollment.
- Patients who received EGFR monoclonal antibody or EGFR tyrosine kinase inhibitor;
- Patients who received other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1;
- Patients with brain metastases with symptoms or symptom control for less than 3 months;
- Patients with any severe and/or uncontrolled diseases, including patients with unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); patients with grade I or higher myocardial ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 480ms) and grade I cardiac insufficiency; active or uncontrolled severe infection; liver disease such as decompensated liver disease, active hepatitis B (HBV-DNA ≥ 104 copy number / ml or 2000 IU / ml) Or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method);
- Imaging studies have shown that the tumor has invaded the important vascular circumference or that the patient is likely to invade the important;
- Pregnant or lactating women.
- Patients with other malignant tumors within 5 years(Except for skin basal cell carcinoma and cervical carcinoma in situ that have been cured).
- Patients with a history of psychotropic substance abuse who are unable to quit or have a mental disorder.
- Patients who have participated in other drug clinical trials within four weeks.
- According to the investigator's judgment, the patients with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study.
- Researchers believe that it is not suitable for inclusion. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nimotuzumab + SHR-1210
|
SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years. Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: up to 1 year
|
From date of randomization until the date of death from any cause
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival(OS)
Time Frame: up to 2 year
|
From date of randomization until the date of death from any cause
|
up to 2 year
|
Progression-free Survival (PFS)
Time Frame: up to 2 year
|
From date of randomization until the date of first documented progression or date of death from any cause
|
up to 2 year
|
Disease Control Rate (DCR)
Time Frame: up to 1 year
|
Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD)
|
up to 1 year
|
Duration of response (DOR)
Time Frame: up to 2 year
|
Refers to the time when the tumor is first evaluated as CR or PR until the first assessment is PD (Progressive Disease) or any cause of death.
|
up to 2 year
|
Time to response (TTR)
Time Frame: up to 1 year
|
up to 1 year
|
|
9-month survival rate
Time Frame: up to 9 month
|
up to 9 month
|
|
12-month survival rate
Time Frame: up to 12 month
|
up to 12 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Nimotuzumab
Other Study ID Numbers
- FQX-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Carcinoma
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
Fujian Medical University Union HospitalNot yet recruitingEsophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IVChina
-
The First Affiliated Hospital of Henan University...Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia Central Hospital; Military 150 Hospital and other collaboratorsActive, not recruitingStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaboratorsRecruitingEsophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage IIIChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityCompletedThoracic Esophageal Squamous Cell CarcinomaChina
Clinical Trials on Nimotuzumab + SHR-1210
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingResectable Esophageal Squamous Cell Carcinoma
-
Qian ChuJiangsu HengRui Medicine Co., Ltd.RecruitingSarcomatoid Carcinoma of LungChina
-
Guangdong Association of Clinical TrialsNot yet recruitingNon-small Cell Lung Cancer
-
Beijing Sanbo Brain HospitalRecruitingPrimary Central Nervous System LymphomaChina
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedLung NeoplasmsChina
-
Guangdong Association of Clinical TrialsUnknown
-
Harbin Medical UniversityJiangsu HengRui Medicine Co., Ltd.Unknown
-
Yanqiao ZhangNot yet recruiting